List of works by Shelly T Karuna

1272. Feasibility and Successful Enrollment in Proof-of-Concept Trials to Assess Safety and Efficacy of a Broadly Neutralizing Monoclonal Antibody, VRC01, to Prevent HIV-1 Acquisitionin in Uninfected Individuals

A descriptive analysis of transgender participants in phase 1-2a trials of the HIV Vaccine Trials Network (HVTN) in the United States and Peru

scientific article published on 05 June 2019

Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk

scientific article published on 01 November 2019

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

scientific article

Behavioral risk assessment in HIV Vaccine Trials Network (HVTN) clinical trials: a qualitative study exploring HVTN staff perspectives

scientific article published on 13 July 2013

Broadly Neutralizing Antibodies for HIV Prevention

scientific article published on 01 January 2020

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial

scientific article published on 01 November 2019

Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection

scientific article published on 29 January 2020

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine

scientific article

Engaging Transgender People in NIH-Funded HIV/AIDS Clinical Trials Research

scientific article published on August 2016

HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies

scientific article published on 30 July 2015

HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial

scientific article

Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial

scientific article published on 12 February 2017

Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination

scientific article published on 23 December 2019

Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants

scientific article published on July 2013

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials.

scientific article

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial

scientific article published on 8 January 2018

Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features

article

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial

scientific article published on 07 October 2019

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants

scientific article

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.

scientific article published on 17 November 2017

Sources of racial/ethnic differences in awareness of HIV vaccine trials.

scientific article

Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial

scientific article published on 7 April 2015

The inner foreskin of healthy males at risk of HIV infection harbors epithelial CD4+ CCR5+ cells and has features of an inflamed epidermal barrier

scientific article

Transient Peripheral Immune Activation follows Elective Sigmoidoscopy or Circumcision in a Cohort Study of MSM at Risk of HIV Infection

scientific article

Use of placebos in Phase 1 preventive HIV vaccine clinical trials

scientific article

Paulina is supported by:

About Paulina

Help